NewTimeSpace News: QL Biopharmaceutical needs to supplement explanations for its overseas listing filing covering the basis for identifying a single controlling person under the concerted action agreement, pricing fairness for new shareholders, aggregation of shareholdings for related shareholders, compliance of equity incentives, patent utilisation and foreign investment access compliance including stem cell-related review, compliance of outbound investment procedures, and title status of full-circulation shares. Legal counsel shall conduct comprehensive look-through verification and issue legal opinions on the aforesaid matters.
NewTimeSpace News: XREAL Ltd. has recently received supplementary material requirements from the China Securities Regulatory Commission regarding its filing for overseas securities offering and listing. The inquiries cover five major matters: compliance of VIE structure dismantling, pricing fairness for new shareholders, compliance of equity incentive schemes, litigations and customs investigations involving domestic operating entities, and consistency of offering volume.
NewTimeSpace News: Amos Food (Group) Co., Ltd. recently received supplementary material requirements from the China Securities Regulatory Commission (CSRC) in relation to its filing application for overseas securities offering and listing. The Company is required to engage legal counsel to conduct verification and issue clear legal opinions covering multiple matters, including pricing rationality of capital increases and equity transfers, existence of historical shareholding nominee arrangements, fairness of share subscriptions by new shareholders in the latest 12 months, whether business scopes involve sectors subject to foreign investment restrictions, foreign exchange and investment compliance of overseas subsidiaries, progress of approval and filing procedures for overseas fund-raising projects, as well as the title status of shares held by shareholders participating in the full circulation scheme.
NewTimeSpace News: Arrano International Holdings Limited submitted a listing application to HKEX GEM on 24 July, with Lince Securities Finance acting as the sole sponsor. The Company is a Hong Kong security services provider that has undertaken security operations for large-scale infrastructure projects including the Three-runway System, with the maximum initial contract value reaching HK$295.5 million during the track record period. The Company has forayed into robotic security solutions and set up a joint venture with Guangzhou Huilun to develop security robots.
NewTimeSpace News: SHEIN Global Holdings Limited passed the Hong Kong Stock Exchange listing hearing on 26 July. Goldman Sachs, Morgan Stanley and JPMorgan act as joint sponsors. As the world’s largest online fashion destination, the Company served around 273 million active customers across approximately 160 markets in 2025, posting net revenue of USD41.8 billion with more than 2 million apparel styles available. The Company pioneered the Large-scale Automated Small-batch Quick-response (LATR) operating model.
NewTimeSpace News: NASN Intelligent Tech (Zhejiang) Co., Ltd. passed the Hong Kong Stock Exchange listing hearing on 26 July, with Haitong International and BOCI International acting as joint sponsors. The Company develops intelligent driving motion control technology. It is China’s first enterprise to deploy electric brake booster solutions for the commercial operation of L4 autonomous vehicles. Based on 2025 sales volume, it ranks among China’s top three domestic-owned drive-by-wire brake suppliers and the second-largest independent third-party domestic supplier.
NewTimeSpace News: PrimeGenX Therapeutics Co., Ltd. submitted its second listing application to HKEX on 24 July, with CITIC Securities and Minsheng Capital serving as joint sponsors. Founded in 2016, it is a biotech firm focused on local delivery targeted therapies for immune inflammatory diseases. Its core asset PG-011 (Pumecitinib), a small-molecule JAK1/2 inhibitor, is being developed in two formulations: pumecitinib gel for mild-to-moderate atopic dermatitis and pumecitinib nasal spray for moderate-to-severe allergic rhinitis. The Company has 63 R&D personnel, accounting for 73.2% of all full-time employees.
NewTimeSpace News: Zhongan Information Technology (Shenzhen) Co., Ltd. submitted a listing application to HKEX on 24 July, with ICBC International and Guolian Securities International acting as joint sponsors. The Company is an enterprise-focused AI solution provider. Its cumulative client base expanded from 88 at end-2023 to 361 at end-2025, representing a compound annual growth rate of 102.5%, and further rose to 409 as at 31 May 2026.
NewTimeSpace News: Guangzhou Novaken Pharm Co., Ltd. submitted its second listing application to the Hong Kong Stock Exchange on 24 July, with Guotai Junan International acting as the sole sponsor. Founded in 2007, it is a clinical-stage pharmaceutical enterprise focusing on the development and commercialisation of improved new drugs. Its core product DHMP (Dexmedetomidine Hydrochloride Microneedle Patch) is China’s first dissolvable microneedle pharmaceutical patch approved for clinical trials and the only candidate progressing into Phase II clinical studies to date. Another core asset XJN010 is the first investigational product targeting off episodes of Parkinson’s Disease to secure clinical trial approval in China.
NewTimeSpace News: According to HKEX disclosures, the GEM listing application of Changle Holdings Limited submitted on 23 January 2026 has recently lapsed upon expiry of the six-month validity period. Legend Corporate Finance Limited acted as the sole sponsor at the time of filing. The Company is a Singapore-incorporated general contractor undertaking construction and renovation works, holding a GB1 licence issued by the Building and Construction Authority.
NewTimeSpace News: According to HKEX filings, the Main Board listing application of Zhejiang IPLUSMOBOT Technology Co., Ltd. submitted on 23 January 2026 has recently lapsed upon the expiry of the six-month validity period. CICC acted as the sole sponsor at the time of submission. According to CIC Consulting, measured by order value, the Company ranks among the world’s top 10 intelligent mobile robot suppliers, top five globally and top three in China within the industrial intelligent mobile robot segment.
NewTimeSpace News: According to HKEX disclosures, the Main Board listing application of Dizal (Jiangsu) Pharmaceutical Co., Ltd., submitted on 23 January 2026, has recently lapsed upon expiry of the six-month validity period. Goldman Sachs and Huatai International acted as joint sponsors at the time of filing. The Company is a commercial-stage biopharmaceutical firm. Its flagship product ZEGFROVY® is the world’s only approved small-molecule targeted drug for the treatment of EGFR exon 20 insertion mutation lung cancer.
NewTimeSpace News: The listing application of Shanghai Junyi Industrial Automation Co., Ltd. submitted to HKEX on 23 January 2026 has lapsed upon expiry of the six-month validity period. Guotai Junan International acted as the original sole sponsor. The Company is a well-known mainland China integrator of robotic automation systems and solutions, supplying smart manufacturing solutions to global automotive manufacturing and new energy battery industries, with customers covering markets including China, Germany, the United States, France, the United Kingdom, Spain and multiple other regions.
NewTimeSpace News: Leadrive Technology (Shanghai) Co., Ltd. resubmitted its listing application to HKEX on 22 July, with CITIC Securities and Haitong International acting as joint sponsors. The Company is a technology-driven supplier of electric drive control solutions focusing on new energy passenger vehicles. According to Frost & Sullivan, measured by 2025 sales revenue, the Company ranks No.1 in China for dual-motor controllers and primary drive power bricks. It has secured 59 project nominations from 15 OEMs, with its solutions deployed across 92 vehicle models.
NewTimeSpace News: Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. filed its listing application with HKEX on 22 July, with CICC and Sinolink Securities (Hong Kong) acting as joint sponsors. According to Frost & Sullivan, measured by 2025 revenue, the Company is China’s largest provider of temperature-controlled supply chain services for pharmaceutical and life science industries, and the only Chinese enterprise among the world’s top ten service providers for clinical trial temperature-controlled supply chains, serving over 7,000 clients.
NewTimeSpace News: Guangxi Baifei Dairy Co., Ltd. submitted its listing application to HKEX on 22 July, with GF Securities acting as sole sponsor. The Company is a leading Chinese buffalo dairy player. Its core brand Baifei Luoranks No.1 in China’s buffalo dairy industry with a 30.1% market share. According to Frost & Sullivan, the Group commands a 31.0% share of liquid buffalo milk market, 31.8% of ambient liquid buffalo milk market and 39.1% of online liquid buffalo milk sales, claiming top position in all three segments.
